Creative Biolabs Integrates CAR-T and TIL Therapy Platforms to Advance Cancer Immunotherapy
TL;DR
Creative Biolabs' integrated CAR-T and TIL platforms provide biotech startups with a competitive edge through end-to-end development of next-generation cellular immunotherapies.
Creative Biolabs combines scientific rigor with advanced technologies like Smart CAR platforms and precision TIL profiling for systematic development of cellular immunotherapies.
This integration accelerates the development of safer, more effective cancer treatments, offering new hope for patients with advanced solid tumors and melanoma.
Creative Biolabs pioneers smart CAR designs including Dual CARs and Logic-gated CARs that can penetrate solid tumors' defenses with minimal toxicity.
Found this article helpful?
Share it with your network and spread the knowledge!
Creative Biolabs announced the full integration of its one-stop-shop CAR-T and TIL therapy development platforms, providing researchers and biotech startups with seamless, end-to-end services for developing next-generation cellular immunotherapies. This integration comes at a critical time when recent regulatory approvals, including the FDA approval of lifileucel (Amtagvi) as the first tumor-infiltrating lymphocyte therapy for advanced melanoma, have demonstrated the therapeutic potential of cell-based cancer treatments.
The company's Smart™ CAR platform represents a significant advancement in CAR-T therapy development, offering construction services for next-generation CAR designs including novel constructs such as Dual CARs, TriCARs, Modular CAR, and Logic-gated CAR systems. According to a principal scientist at Creative Biolabs, the platform supports first- through fourth-generation CARs along with armored variants that secrete immune modulators like IL-12, with each construct tailored to specific tumor biology and immune microenvironment requirements for optimal efficacy and minimal toxicity.
Creative Biolabs addresses one of the most challenging obstacles in cancer immunotherapy through its CAR-T platform targeting solid tumors, which employs bispecific CARs, checkpoint-resistant designs, and optimized delivery systems to improve tumor infiltration and persistence. The company's integrated approach combines scientific rigor with technological innovation and clinical scalability, positioning it at the forefront of engineered immune cell development.
The tumor-infiltrating lymphocyte therapy platform provides comprehensive services for precision cell profiling and expansion, representing a breakthrough innovation in treating solid tumors. A company representative noted that TIL therapy is exceptionally well-positioned to identify heterogeneous neoantigens, while Creative Biolabs also leads in TIL-based antibody discovery using patient-derived B cells to develop fully human antibodies with high specificity and therapeutic value. The company utilizes cutting-edge genetic and cellular engineering technologies to ensure TILs are highly potent and specifically targeted against cancer cells, facilitating accelerated and stable translation from research to clinical application. Researchers can learn more about these integrated platforms by visiting https://www.creative-biolabs.com/car-t/.
Curated from 24-7 Press Release
